Brainstorm Cell (BCLI) ALS Trial Results 'Robust' - Maxim Group

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. JBHT
3. CRWV
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. USB
10. SPY

Go back to Brainstorm Cell (BCLI) ALS Trial Results 'Robust' - Maxim Group

Brainstorm Cell Therapeutics (BCLI) Announces NurOwn Phase 2 Met Primary Endpoint in ALS

July 18, 2016 8:16 AM EDT

BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) announced results from the recently completed U.S. randomized, double-blind, placebo-controlled phase 2 Study of NurOwn in Patients with ALS. The study achieved its primary objective, demonstrating that NurOwn was safe and well tolerated. NurOwn also achieved multiple secondary efficacy endpoints, showing clear evidence of a clinically meaningful benefit. Notably, response rates were higher for NurOwn-treated subjects compared to placebo at all time points in the study out to 24 weeks.

"We are very encouraged by these Phase 2 data that show that NurOwn cell therapy is safe and that... More